{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    15,
    35,
    36,
    39,
    40,
    43
  ],
  "modelUsed": "gemini-3-pro-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference to Section 2 lists the Schedule of Activities"
      },
      {
        "id": "ref_2",
        "name": "Lab Tests Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference to Appendix 2 lists the laboratory tests"
      },
      {
        "id": "ref_3",
        "name": "Blood Sampling Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference to Appendix 5 provides a summary of the maximum number and volume of invasive samples"
      },
      {
        "id": "ref_4",
        "name": "Plasma Glucose Method Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1",
        "sectionTitle": "Efficacy Assessments",
        "description": "Reference to Section 9.2.3 for plasma glucose measurement description"
      },
      {
        "id": "ref_5",
        "name": "Edinburgh Hypoglycemia Scale Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.3",
        "sectionTitle": "Exploratory Efficacy Assessments",
        "description": "Reference to Appendix 7 for Edinburgh Hypoglycemia Scale"
      },
      {
        "id": "ref_6",
        "name": "Clarke Survey Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.3",
        "sectionTitle": "Exploratory Efficacy Assessments",
        "description": "Reference to Appendix 8 for Clarke Hypoglycemia Awareness Survey"
      },
      {
        "id": "ref_7",
        "name": "Treatment Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.2",
        "sectionTitle": "Glucagon Administration",
        "description": "Refer to Section 7 for details regarding treatments"
      },
      {
        "id": "ref_8",
        "name": "Nasal Questionnaire Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.2.1",
        "sectionTitle": "Nasal LY900018 Administration",
        "description": "Reference to Appendix 6 for Nasal and Non-nasal Score Questionnaire"
      },
      {
        "id": "ref_9",
        "name": "External Document Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.4",
        "sectionTitle": "Treatment of Overdose",
        "description": "Refer to the LY900018 IB and GlucaGen Summary of Product Characteristics"
      },
      {
        "id": "ref_10",
        "name": "Hepatic Monitoring Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.5.5.2",
        "sectionTitle": "Hepatic Safety",
        "description": "Reference to Appendix 4 for liver tests"
      },
      {
        "id": "ref_11",
        "name": "Lab Test Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Schedule of Activities",
        "sectionTitle": "Clinical Lab Tests",
        "description": "See Appendix 2, Clinical Laboratory Tests, for details"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidential Information",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "Patients do not need to fast for samples at screening or follow-up. At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 16
      },
      {
        "id": "annot_3",
        "text": "Serum pregnancy test will be performed at screening. Urine pregnancy test will be performed at every admission period and follow-up visit if applicable.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 16
      },
      {
        "id": "annot_4",
        "text": "Additional tests can be done at the discretion of the investigator.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 16
      },
      {
        "id": "annot_5",
        "text": "TE ADAa",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 16
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "I8R-JE-IGBJ(a)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly. Original signature date 26 October 2017.",
        "amendmentNumber": "(a)"
      }
    ],
    "summary": {
      "referenceCount": 11,
      "annotationCount": 5,
      "versionCount": 1
    }
  }
}